Solution Group Berhad’s which is the ASEAN manufacturing partner of CanSino Biologics Inc’s has obtained approval from the Ministry of Health to begin private sales of the CanSino Covid-19 vaccine, known as Convidecia.
CanSino’s Convidecia will be made available to the private market such as hospitals, clinics, as well as the corporate and manufacturing sectors in Malaysia starting from early December 2021. It will be available in both single dose and three doses per vial configuration. Solution is in the process of appointing a Good Distribution Practice (“GDP”) certified partner to ensure that the vaccine will be professionally handled and distributed.
Dato’ Dr. Mohd Nazlee Bin Kamal, Deputy Group Managing Director, said, “We would like to thank MOH for the timely approval as we have been receiving tremendous interest from the private sector for Convidecia which has an excellent safety profile and has proven to be highly effective as a homologous and heterologous booster in studies carried out in China and Argentina.
To date, Solution has completed the delivery of 2.9 million doses of the COVID-19 vaccine to MOH, with the remaining 600,000 doses to be delivered by mid-December.
The group has applied to NPRA for Convidecia to be used as a booster shot in the National Immunisation Programme and hopes to receive approval soon.
